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The hepatotropic influence of cyclosporine 
Vincenzo Mazzaferro, MD, Kendrilr. A. Porter, MD, Carlo L. Scotti-Foglieni, MD, 
Raman Venkataramanan, PhD, Leonard Makowka, MD, PhD,· Lorenzo Rossaro, MD, 
Antonio Francavilla, MD, Satoru Todo, MD, David H. Van Thiel, MD, and 
Thomas E. Starzl, MD, PhD, Pittsburgh, Pa., and London, England 
The effect of cyclosporine on liver regeneration has been investigated in 25 dogs that 
underwent an end-to-side portacaval shunt (Eck fistula) followed by 4 days continuous 
infusion of the drug into the left branch of the portal vein. Three different cyclosporine 
infusion rates were used: 0.06, 0.6, and 4.0 mg/kg/day. Control animals received the 
intravenous vehicle of cyclosporine at the same rate as the treated animals; a second 
control group received insulin, 0.42 units/kg/day. Hepatocyte JH-thymidine-labeled 
mitoses (index of hyperplasia) and hepatocyte volume (index of hypertrophy) were 
studied in the left (infused) and right (control) lobes in each animal. Cyclosporine 
vehicle had no measurable effect on hepatocytes that suffered typical atrophy and 
moderate increase in mitotic index after the Eck fistula. Cyclosporine infusion 
stimulated cell renewal significantly and restored hepatocyte size in the infused lobes 
with a dose-response relation. Similar positive effects were observed in the right 
(nonperfused) lobes, although they were less than those in the left (infused) lobes. This 
was because of an unmistakable spillover of cyclosporine from the infused lobes, 
especialiy in the large-dose group. No sign of hepatotoxicity was detected at any 
cyclosporine infusion rate. Cyclosporine has a remarkable hepatotropic effect that may 
be helpful in the context of liver transplantation. (SURGERr 1990;107:533-9.) 
From the Departments of Surgery and Medicine, the School of Pharmacy, and the Veterans 
Administration Hospital of the UniverSity Health Center of Pittsburgh, Pittsburgh, Pa., and the 
Department of Pathology, Saint "vlary's Hospital and Medical School, London, England 
CYCLOSPORISE, A CYCLIC L:SDECAPEPTIDE of fungal 
origin, is an inhibitor of T-Iymphocyte activation I and 
currently is the most important immunosuppressive 
drug used in organ transplantation. The lack of serious 
hepatotoxicity of cyc1osporine at therapeutic dosages is 
a distinctive feature of this drug,2-s although both minor 
and major changes in hepatic function have been 
described. 2. 3 
mately when it becomes the target of the recipient's im-
munologic response. 6.6. The abiIi ty of the liver to repair 
itself from such damage probably is an important prog-
nostic determinant. In addition, the transplanted liver is 
expected to, and can, adjust its volume to the size 
requirement of the recipient. 7• 8 This requires intact 
growth-control mechanisms including the capacity for 
regeneration. 
A more complete understanding of the effects of cy-
c1osporine on the liver is desirable in the context of he-
patic transplantation. An allograft liver is subject to in-
jury during the events of donor death, procurement, cold 
preservation, reperfusion in the recipient, and ulti-
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We have demonstrated that cyclosporine does not 
adversely affect hepatic regeneration after a partial 
hepatectomy in rats but that it actually enhances this 
response.9 This finding has been confirmed repeated-
ly.IO·14 In this study the cyclosporine effect on regener-
ation has been examined with a standardized canine 
experimental model (Eck fistula) that has been used in 
the past to study the impact of hepatotropic substances 
on liver health and the capacity for regeneration. IS. 16 
MATERIAL AND MEmODS 
Animals and surgical procedures. Twenty-five 
adult female beagle dogs weighing between 8.3 and 13 
kg (median, 10.5 kg) were purchased from Hazleton 
Research Products, Cumberland, Va. and conditioned 
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Fig. 1. Surgical model of Eck fistula (portacaval shunt). The 
model in effect splits the liver into two fragments that differ 
only by what is infused into the tied off left portal vein branch. 
Therefore treated (left) and control (right) hepatocytes are 
present in the same liver. 
at the University Animal Research Facility for at least 
7 days before operation. The surgical procedures always 
were performed between 8:30 and 11 :30 AM to eliminate 
the variables caused by diurnal rhythms. 17 The anes-
thetic used during the original operation and all subse-
quent manipulations was sodium pentobarbital (25 to 
30 mg/kg intravenously) followed by orotracheal ad-
ministration of halothane (0.5% to 1.5%) mixed with 
nitrous oxide and oxygen (N20/02, 66%/33%). The 
dogs' blood pressure and arterial blood gases were 
monitored with the aid of an arterial catheter. 
An Eck fistula model was used that in effect splits the 
liver into two fragments. These fragments differ only by 
what is infused into the tied-off main right and left 
portal vein branches. IS. 1M A large side-to-side porta-
caval shunt was constructed with continuous vascular 
suture, and this was converted to a functional end-
to-side shunt by ligation of the portal vein above the 
anastomosis (Fig. 1). The main right and left portal 
veins also were ligated. A 2.4 mm (internal diameter) 
soft infusion catheter was inserted 1 cm into the left 
branch (Fig. 1) and led through the abdominal wall to 
a small battery-charged and calibrated infusion pump 
(Cormed II AIF, Cormed Inc., Medina N.Y.). The 
pump was incorporated into a light body cast (Chatam 
Medical Arts, Los Angeles. Calif.) that allowed free 
movement and self-feeding of the dog during the post-
operative period. Cyclosporine was infused continu-
ously into the left hepatic lobe through this catheter. It 
was previously established 18 that saline control infu-
Surgery 
.\lav 1990 
sions into the tied-off right portal vein had no effect on 
the right hepatic fragment. The particular advantage of 
this model is that regeneration-inducing substances can 
be evaluated by their selective infusion in one of the 
portal vein branches. The effects in the infused hepatic 
lobes can be compared with those in the uninfused lobes. 
Each animal serves as its own control because in this 
model the noninfused and the treated hepatocytes are in 
the same liver. 
During the first 24 hours after surgery, the dogs were 
given sugar water (sucrose, 82 gm/L) followed thereaf-
ter by regular diet. Blood samples were obtained daily 
from a front leg vein, and the blood was processed im-
mediately. Cyclosporine blood levels were determined 
by whole-blood high-performance liquid chromato-
graphy.20 Alanine aminotransferase (AL T), total biliru-
bin, albumin, and creatinine levels also were measured. 
Four days after the portacaval shunt had been 
created, the animals were administered 0.2 mCi/kg of 
intravenous (CH3- 3H)thymidine with specific activity 
of 80 to 90 Ci/mmol (New England Nuclear, Boston, 
Mass.). Two hours later under general anesthesia, the 
abdomen was reentered and blood for measurement of 
cyclosporine level was collected from the vena cava be-
low the liver and the left hepatic vein. The cyclosporine 
concentration in the left hepatic vein was thought to re-
flect drug that had escaped first-pass clearance by the 
left hepatic lobes, whereas the level in the vena cava re-
flected cyclosporine after systemic distribution of what-
ever cyclosporine had passed through the left hepatic 
lobes. 
Biopsy specimens were obtained from left and right 
lobes of the liver. These were immediately fixed in 10% 
normal buffered formalin. The dogs were then killed 
with an anesthetic overdose to which potassium chloride 
was added. The cyclosporine infusion into the left por-
tal vein was not interrupted until this time. 
Experimental groups 
Group 1 (n = 5). The vehicle used to solubilize cy-
closporine is a nonionic surfactant (Cremophor EL) and 
ethanol (95'0) in normal saline solution (66, 33%). This 
vehicle was infused continuously into the left portal vein 
at a rate equivalent to that of a cyclosporine infusion rate 
of 0.06 mg/kg/day (one animal), 0.6 mg/kg/day (two 
animals), and 4 mg/kg/day (two animals). Because 
there was no effect at any infusion rate, the results were 
pooled. 
Group 2 (n = 6). CycIosporine (SANDIMMUNE 
intravenous solution, Sandoz Pharmaceuticals Inc., 
East Hanover, N.].) was given at a dose of 0.06 
mg/kg/day beginning within 30 minutes of completion 
of the portacaval shunt. The infusion volume never ex-
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Table L Hepatocyte mitoses by autoradiography after intraportal continuous infusion of cyclosporine into the left 
portal vein of dogs with Eck fistula 
Jfitosis 
(no. of labeled hepatocytes per 
1000 hepatocytes (mean ± SDI) t 
No. of C)'c/osporine Right Left 
Group experiments infusion * lobes lobes p Value 
1 5 o (Controls); 4.11 ± 0.28 4.16 ± 0.58 NS 
2 6 0.06 mg/kg/day 4.0 ± 0.40 4.87 ± 0.52 NS 
3 6 0.6 mg/kg/day 4.37 ± 0.45 5.19 ± 0.46 <0.003 
4 6 4.0 mg/kg/day 5.44 ± 0.65 6.33 ± 0.84 <0.04 
5 2 o (Insulin, 4.5 ± 1.0 14.3 ± 1.1 <0.001 
0.42 units/kg/day) 
• ANOVA <all l"yclosporinK-t~attd "" ... us cuntrul animals): brtwrrn groups, F - 10.0445; within groups, " - 0.0004 
tIn 17 normal dogs the mitoses in Idt and right 1000 were 1.6 :I: 0.4 and 1.6 :I: 0.5, respectively. The increase in mitoses caused by Eck fistula is known to br 
significant. tl, .9 
;COntrol dogs received only the vehides of cydosportnt. 
ceeded 28 ml during a 24-hour period. The solution ad-
ministered to each dog was prepared in the morning and 
placed in a 40 ml pump reservoir bag. A fresh reservoir 
I 
was used every day. 
Group 3 (n = 6). Group 3 was the same as group 2 
except that the cyclosporine dose was 0.6 mg/kg/day. 
Group 4 (n = 6). Group 4 was the same as group 2 
except that the cyclosporine dose was 4.0 mg/kg/day. 
Group 5 (n = 2). The animals were given a contin-
uous left portal branch infusion for 4 days of 0.42 
units/kg/day of purified insulin. The objective was to 
see if previous observations with intralobar insulin in-
fusion in dogs with Eck fistulas lS could be repeated. 
Pathologic studies. After fixation in formalin, the 
liver tissue was processed and stained by standard he-
matoxylin-eosin staining technique. Autoradiography 
was carried out with Kodak NTB2liquid emulsion and 
an exposure time of at least 30 days. The number of 
mitoses, as an index of hepatocyte regeneration, was 
determined by counting the number of 3H-thymidine-
labeled nuclei per 1000 hepatocytes. The size of indi-
vidual hepatocytes (index of hypertrophy) was deter-
mined by tracing out a large number of midzonal liver 
cells projected on standard-thickness paper, cutting out 
the individual silhouettes, and weighing each. This 
method has been shown to be accurate for determining 
hepatocyte cell size and has been validated by planim-
etry and studies of unicellular organisms, the size of 
which has been determined directly. IS. 16.21 In normal, 
unaltered dogs, about 1.5 ± 0.5 mitoses per 1000 
hepatocytes are present in the liver, with the size of 
midzonal hepatocytes being about 0.16 ± 0.01 size 
units. IS. IS. J <) The exceptional reproducibility of these 
values and the very tight standard deviations make it 
easy to identify changes caused by drugs or other exper-
imental variables. 
Statistical analysis. All data are reported as mean 
values ± SD. For analysis of variance (ANOVA), the 
two main populations were control dogs (receiving ve-
hicles) versus cyclosporine-treated dogs. A value of the 
F test greater than 3.0 (p < 0.Ql) was considered 
significant. The Student t test was employed in individ-
ual experimental groups to compare differences be-
tween right and left lobes. A p value less than 0.05 was 
considered significant. 
RESULTS 
Control studies 
Cyc/osporine vehicle. Cyclosporine vehicle had no 
measurable effect at any of the infusion rates. In the 
animals infused only with cyclosporine carrier, the he-
patocytes had the typical changes of Eck fistula, which 
were identical in the right and left lobes. IS. ~~K~~ The rate 
of mitoses was nearly three times greater than normal 
(Table I, group 1). Hepatocyte atrophy was apparent 
from the abnormally small-size units (Table II, group 
1). The hepatocytes were irregular in shape, depleted of 
glycogen, and shrunken. Moreover, the liver was grossly 
smaller than usual and the reticulin framework was 
condensed around the central veins. The Kupffer cells 
were enlarged and filled with ceroid and lipofuscin. No 
morphologic changes suggesting hepatotoxicity were 
seen in the livers of the animals infused continuously 
with the cyclosporine vehicle at any infusion rate. 
Insulin control. When insulin was given into the left 
portal vein, the left lobes were spared the atrophy and 
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Table II. Hepatocyte size after intra portal continuous infusion of cyclosporine in dogs with Eck fistula 
Treatment Cell size units (mean ± SD)t 
No. of Dog weight (cyclosporine infUSIon 
Group experiments (mean kg ± SD) rate) • Right lobes Left lobes p Value 
5 10.2 ± 1.8 o (Controls) 0.1085 ± 0.01 0.1059 ± 0.01 NS 
2 6 10.2 ± 0.9 0.06 mg/kg/day 0.1090 ± 0.01 0.1106 ± 0.01 NS 
3 6 10.1 ± 1.1 0.6 mg/kg/day 0.1129 ± 0.006 0.1242 ± 0.01 <0.04 
4 6 10.5 ± 1.3 4.0 mg/kg/day 0.1381 ± 0.02 0.1602 ± 0.01 <0.05 
5 2 10.4 ± 0.8 o (Insulin, 0.1048 ± om 0.1588 ± 0.01 <0.001 
0.42 units/kg/day) 
- ANOV" <all cyclospllrine-treated versus mntrol animals): betwren groups, F -18.103; within groups, p -0.001. 
tin normal dogs. hepatocyte size units are 0.16 :!: 0.0 I. 15 
Table ill. Cyclosporine blood levels after 4 days of 
continuous intraportal infusion 
Infusion Left 
rate hepatic Peripheral 
(mg/kg/day) vezn blood 
0 
0.06 Undetectable Undetectable 
0.6 Undetectable· Undetectable 
4 278.9 ± 46.4 ng/ml 263.5 ± 52.4 ng/ml 
-Exl"p';on was one of the six animals whose hepatic vein level was 70 ngim!. 
CndeteL·table means a cyciosporine concentra,;on <SO ngiml determined by a 
whole-blond high-performance liquid chroma''''Jraphic method. 
organelle deterioration that occurred on the right side 
(Table II, group 5); in addition, there was a striking 
proliferative response (Table I, group 5). These results 
were identical to those obtained 14 years ago. 18 
Cyclosporine infusion 
HistopathoLogic studies. None of the liver specimens 
obtained from cyclosporine-treated animals showed any 
evidence of hepatocellular damage. On the contrary, the 
cyclosporine infusions benefited the infused and the 
noninfused lobes. The ANOVA of all liver samples from 
cyclosporine-treated animals versus the samples from 
animals infused with carrier only showed a significant 
increase in the hepatocyte mitotic index (Ftest = 10.04; 
P = 0.0004) (Table I) and in hepatocyte size (F 
test = 18.10; P - 0.001) (Table 11). A dose-response 
relation was evident, the most striking results being with 
the largest milligram per kilogram per day infusion rate. 
The directly infused left lobes had a significantly 
greater proliferative response and larger hepatocytes 
than had the right lobes (Tables I and II). However, 
there was an unmistakable spillover to the right lobes in 
the larger-dose groups 3 and 4. The same spillover 
probably occurred in all of the cyclosporine-treated an-
imals because the right (non perfused) lobes had changes 
similar to, although less than, those in the left (infused) 
lobes (Tables I and II). The increase in hepatocyte pro-
liferation in either the right or left lobes was minor at 
any cyclosporine dose compared with the proliferative 
response to insulin (Table I). In contrast, maintenance 
of hepatocyte size and preservation of organelle quality 
was a striking feature of the cyclosporine-infused lobes 
(Table II). 
Cyclosporine bLood leveLs. CycJosporine was unde-
tectable in either the hepatic vein or systemic venous 
blood except with the largest dose. Only one dog of 
group 3 had a detectable level of cyelosporine in the left 
hepatic vein at the time of death. When 4 mg/kg/day 
was given into the left portal branch, the blood level rose 
to immunosuppressive levels at both sampling sites 
(Table III). 
Hepatic and renaL function tests. Neither the cyelo-
sporine doses nor the infusion of vehicle had an effect on 
bilirubin, albumin, AL T, or creatinine levels (Fig. 2). 
Transaminasemia developed during 4 days of the 
experiment in control animals and in treated animals, 
but this is a known response to Eck fistula. 
DISCUSSION 
After liver transplantation, cyelosporine is adminis-
tered orally as soon as the recipient is able to eat. What-
ever cyclosporine is absorbed can reach the general cir-
culation only after passing through the liver by the por-
tal vein. It is known that greater than 90% of the drug 
undergoes extensive hepatic metabolism26 and is ex-
creted solely into bile. Cyclosporine apparently enters 
hepatocytes by simple diffusion in a concentration- and 
time-dependent manner:!: because the uptake of the 
drug is not dependent on an energy supply for hepato-
cytes. The bioavailability of the drug averages approx-
imately 30% of the orally administered dose. 28,29 
The portal route of drug delivery that follows oral 
ingestion was simulated in this study. The lowest 
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Fig. 2. Hepatic and renal function test results. No difference between groups is observed. Increase in AL T is 
a known response to Eck fistula. 
infused dose appeared to be below the therapeutic range 
considered desirable clinically because none of the 
infused cyclosporine could be detected in the hepatic 
vein. The largest dose was definitely in the therapeutic 
range and it may even have been excessive. The different 
infusion rates of cyclosporine chosen for this study were 
based on the pharmacokinetics of the drug described in 
animals and human beingsK~oK 2(). ~~K ~Dg 
There appeared to be no harmful consequences of 
delivering cyclosporine straight to the liver at any of 
these doses, and in fact the portion of the liver exposed 
to cyclosporine on first pass had more rapid cell renewal 
and healthier hepatocytes. Similar but ever more strik-
ing findings have been obtained with the same Eck fis-
tula model when insulin I!! or a cytosolic extract from 
regenerating livers3() was infused. The extremely potent 
effect of insulin described previously IS was confirmed in 
the control experiments of group 5. 
The influence of insulin or other substances in 
increasing hepatocyte size, morphologic integrity, func-
tion, and the capacity for regeneration has been referred 
to as hepatotropic. 15. I(). IS. 19. 3(). 31 According to this 
definition, cyclosporine is hepatotropic. The literature 
supporting this conclusion is summarized in Table IV. 
Until now, all of the evidence of a hepatotropic influence 
of cyclosporine has been obtained with partial liver re-
section in rats9• 14; our studies reported herein have con-
firmed that the hyperplasia component of regeneration 
is actually augmented by cyclosporine. 
In this study we have added the additional observa-
tion that hepatocyte size and morphology can be influ-
enced favorably by cyclosporine. The central observa-
tion was that physiologic doses of cyc1osporine were able 
to prevent the atrophy and organelle disruption caused 
by Eck fistula in addition to augmenting the low-grade 
hyperplasia that is characteristic of the liver with Eck 
fistula. I 5.16. IS. 31 
The explanation for these effects is far from clear. It 
is tempting to work backward from what is known about 
the pathogenesis of the Eck fistula injury. Much 
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Table IV. Cyclosporine and liver regeneration: Literature survey 
Reference Model Cyclosporine dose Resulls 
Makowka et al.,9 1986 Rat, 70'70 Hx 2S mg/kg/day p.o. for 7 days 
pre-Hx. 5 mg/kg IV (bolus) 
post-Hx 
Cyclosporine did not inhibit 
enzymatic parameters of hepatic 
regeneration and actually 
potentiated these 
Kahn et al.. 10 1988 
Kim et al.,11.12 1988 
Rat, 70"!o Hx 
Rat, 70% Hx 
Same as Makowka et al. 9 Confirmed Makowka et aI., 1986 
Cyclosporine potentiated mitoses 
whereas azathioprine and 
prednisone suppressed 
10 mg/kg p.o. 1 day before and 
immediately and 24 and 48 
hours post-Hx 
Grant et aI., \3 1988 Rat, 70'70 Hx 10 mg/kg/day p.o. for 10 days 
post-Hx, 20 mg/kg/day p.o. 
for 10 days post-Hx 
Cyclosporine, 10 mg/kg/day, does not 
impair hepatic regeneration; 
cyclosporine, 20 mg/kg/day, 
impaired hepatic regeneration by 
decreasing food intake 
Kahn et al.,14 1989 Rat, 70'70 Hx Same as Makowka et al. 9 Cyc1osporine pretreatment primed the 
liver for a stronger hepatic 
regeneration after Hx, increased 
enzymatic parameters, and 
increased estrogen receptor iictivity 
Mazzaferro et al. (present 
study) 
Dog, Eck fistula 0.06,0.6, and 4.0 mg/kg/day 
continuously for 4 days in 
left portal vein 
Cyc1osporine infused into portal vein 
increases mitotic index and prevents 
hepatocyte atrophy 
IIx. IIrpa,rcwmy; p ..... by mou,h; /I'. inlravrn()us. 
evidence has indicated that the most important factor in 
this injury is the loss of endogenous insulin and other 
less important splanchnic substances that are diverted 
away from the liver by portacaval shunt. IS . 16. 18. 19. 31-.13 
Although all of these studies emphasized the overriding 
role of insulin, multiple splanchnic factors other than 
insulin apparently also can playa cumulative hepato-
tropic role. 15-1 IJ. 11·1~ The ameliorating effects of cyto-
solie extracts on the liver with Eck fistula are not 
thought to be caused by insulin. 3o 
Cyclosporine could be acting directly on the liver. 
However, it could equally well be mobilizing other 
splanchnic or nonsplanchnic hepatotropic factors, or its 
effects could be mediated in ways including immune 
modulation that are barely conceivable at the present 
time. The molecular action of cyclosporine is not known, 
but it is thought to bind to cytoplasmic proteins includ-
ing cydophilin and calmodulin.35•38 T-lymphocytes, 
brain, kidney, and hepatocytes have the highest concen-
tration of cyclophilin in the body, fueling suspicion that 
hepatotoxicity could be common with cyclosporine.38 
Our study provides some assurance that this will not be 
a major concern. 
One puzzling feature of our results was the ease with 
which cyclosporine seemed to leak through the left liver 
lobes and affected the right portion of the liver. In con-
trast, other hepatotropic substances such as insulin 18 
(group 5) and biologically active cytosoPO are so com-
pletely removed with first passage that little effect can 
be seen in the contralateral lobes. The fact that cyda-
sporine easily overcame the first-passage clearance ca-
pacity of the infused lobes accounts for its systemic ef-
fect as an immunosuppressant after oral intake and 
subsequent portal delivery to the liver. 
We acknowledge the help of Del Kahn. ~lichele Barone. 
John Prelich. and Sandra Oks for their assistance during the 
experiments; Bruno Begliomini for statistical analysis; Pro-
fessor Leandro Gennari from Italian :'I:ational Cancer Insti-
tute; and Ms. Donna Ross for editinll; the manuscript. 
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Reply 
The publications by Garcia-Alonzo et al. further confirm 
the original observation by Makowka et al. l and subsequent 
researchers that cyclosporine enhances liver regeneration. The 
chemically unrelated new immunosuppressive agent, FK 506, 
does the same thing,2 and this has further encouraged the kind 
of speculation mentioned by Dr. Garcia-Alonzo that hepatic 
growth control is immune modulated. Otherwise, why would 
two chemically unrelated drugs, which have in common the 
ability to inhibit T-helper lymphocyte activation, affect liver 
regeneration in precisely the same way? In addition, the other 
hepatotrophic qualities of cyclosporine described by Mazza-
ferro et al. 3 are also possessed by FK 5064 
As attractive as the immunomodulation hypothesis may 
have been, such speculation has not been supported by direct 
experimentation. For one thing, we and others have shown 
that hepatic regeneration occurs normally in T-lymphocyte 
deficient nude rats. s Furthermore, FK 506 augments regen-
eration in these animals in the same way as it does in normal 
rats. In either normal or nude rats, natural killer cell function 
is not altered, S eliminating modulation of this cell subset as an 
explanation for the FK 506 effect. 
The alternative explanation for the hepatotrophic qualities 
of cyclosporine and FK 506 (including augmentation of 
regeneration) is nonimmunologic.4• 5 The cytosolic binding 
sites of cyclosporine and FK 506 are distributed throughout 
almost all tissues. Although distinct, these binding sites (called 
cyclophilin and FKBP) are rich in an enzyme called peptidyl-
prolyl isomerase (PPlase), which facilitates protein folding 
and the catalysis of oligopeptide bonds 6 • 7 The alteration 
(probably inhibition) of PPIase activity by cyclosporine and 
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FK 506 is thought to have wide-ranging effects by nonimmu-
nologic mechanisms on many signal transduction and meta-
bolic processes 4 We now believe that these changes, rather 
than those specific to the immune system, hold the key to an 
undt-:-standing of the hepatotrophic action of cyclosporine and 
FK 506. 
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